APO-ATOVAQUONE DIN 02471949
Health Canada record
| Active ingredient(s) | ATOVAQUONE 750 MG |
|---|---|
| Dosage form | Suspension |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | P01AX06 ATOVAQUONE |
| Original market date | |
| Current status date | 16-Jan-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ATOVAQUONE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02466783 | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE TABLETS | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | ATOVAQUONE 250 MG; PROGUANIL HYDROCHLORIDE 100 MG | Marketed |
| 02421429 | ATOVAQUONE PROGUANIL | SANIS HEALTH INC | Tablet | ATOVAQUONE 250 MG; PROGUANIL HYDROCHLORIDE 100 MG | Marketed |
| 02556618 | AURO-ATOVAQUONE | AURO PHARMA INC | Suspension | ATOVAQUONE 750 MG | Marketed |
| 02528495 | GLN-ATOVAQUONE | GLENMARK PHARMACEUTICALS CANADA INC. | Suspension | ATOVAQUONE 750 MG | Marketed |
| 02264935 | MALARONE PEDIATRIC | GLAXOSMITHKLINE INC | Tablet | ATOVAQUONE 62.5 MG; PROGUANIL HYDROCHLORIDE 25.0 MG | Marketed |
| 02217422 | MEPRON | GLAXOSMITHKLINE INC | Suspension | ATOVAQUONE 750 MG | Marketed |
| 02402165 | MYLAN-ATOVAQUONE/PROGUANIL | MYLAN PHARMACEUTICALS ULC | Tablet | ATOVAQUONE 250 MG; PROGUANIL HYDROCHLORIDE 100 MG | Marketed |
| 02380927 | TEVA-ATOVAQUONE PROGUANIL | TEVA CANADA LIMITED | Tablet | ATOVAQUONE 250 MG; PROGUANIL HYDROCHLORIDE 100 MG | Marketed |
| 02009358 | MEPRON TAB 250MG | GLAXO WELLCOME INC. | Tablet | ATOVAQUONE 250 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 20336 | 2018-01-16 | Abbreviated New Drug Submission (ANDS) |
International API supply for ATOVAQUONE
4 valid EDQM Certificates of Suitability from 4 holders. 12 active FDA Drug Master Files.
Request a quote for APO-ATOVAQUONE